India Globalization Capital (NYSE: IGC) was recently featured in an article detailing the company’s strategic move to the cannabis industry and future plans for the company. In the past, IGC was a company primarily focused on the beneficiation of iron ore. That focus changed a few years ago when iron ore prices plummeted, often selling below its cost of production. For the last three years, the company has shifted its focus to tackling the cannabis industry, or more specifically, medical cannabis use. The company is currently developing a portfolio to address epilepsy, cachexia, PTSD, Alzheimer’s, and Parkinson’s. “We came up with several areas where we felt that cannabis could really make an impact. Some of these areas, anecdotally, were already known; for example, pain. We came up with a formulation for pain and we filed a patent for that. It’s cream that can be applied to joints for different kinds of pain. Now, we are going to start doing clinical trials. Our objective is to not do anecdotal stuff, but to actually do clinical trials and eventually do the double blind placebo trials so that we actually have products that have been proven to work,” IGC CEO Ram Mukunda stated in the article.
To view the full article, visit: http://m.benzinga.com/article/9165369
About IGC
In the United States, IGC develops cannabis-based therapies. IGC has assembled a portfolio of patent filings that encompasses the indications of Pain, Seizures, Epilepsy, and Cachexia using phytocannabinoids. The company is based in Bethesda, Maryland. To learn more, visit the company’s website at www.igcinc.us.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CBDWire (CBDW). NNB keeps you up-to-date on active US Public Companies complementary to CBDW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Please see full disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
